IN-115314 vs Zemprocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK1 · full Atopic Dermatitis pipeline

IN-115314

Developed by HK inno.N Corporation

Phase 2 in Atopic Dermatitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Zemprocitinib

Developed by Lynk Pharmaceuticals and partners

Phase 3 in Atopic Dermatitissmall molecule
Reliable signal

NCT06277245 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 356 patients that measured EASI-75 skin clearance and Investigator's Global Assessment response at week 16, the standard efficacy measures for atopic dermatitis. Both the 12 mg and 24 mg doses produced large, statistically significant improvements over placebo on both endpoints.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Eczema Area and Severity Index (EASI-75) at Week 16 (Baseline and Week 16); Investigator's Global Assessment (IGA) score of 0/1 at Week 16 (Baseline and Week 16): EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) (met)

Result source: NCT06277245

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIN-115314Zemprocitinib
EASI-75—Not reported—Not posted · NCT06277245
IGA 0/1 with 2-point improvement—Not reported—Not posted · NCT06277245
EASI-90—Not reported—Not posted · NCT06277245
EASI, % change—Not reported—Not posted · NCT06277245

EASI-75

IN-115314
—Not reported
Zemprocitinib
—Not posted · NCT06277245

IGA 0/1 with 2-point improvement

IN-115314
—Not reported
Zemprocitinib
—Not posted · NCT06277245

EASI-90

IN-115314
—Not reported
Zemprocitinib
—Not posted · NCT06277245

EASI, % change

IN-115314
—Not reported
Zemprocitinib
—Not posted · NCT06277245
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

IN-115314: no structured comparison results are available for Atopic Dermatitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Zemprocitinib
EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) NCT06277245 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IN-115314's landscape · Zemprocitinib's landscape